Abstract
Introduction
COVID-19 is a fast-spreading and alarming global public health issue1. Evans’ syndrome, in contrast, is a rare condition which is characterised by autoimmune disorders, such as autoimmune haemolytic anaemia (AIHA) and immune thrombocytopenia and/or immune neutropenia, which occur simultaneously or consecutively2.
The recommended first-line treatment for Evans’ syndrome is corticosteroids, but these are potentially harmful in patients with COVID-19. On the other hand, intravenous immunoglobulins and other non-immunosuppressive treatments are not adequately successful treatment options in AIHA. In this article, we describe how we treated a case of COVID-19 in a patient who presented with Evans Syndrome.
Downloads
- Abstract viewed - 315 times
- PDF downloaded - 82 times